Navigation Links
OncoSec to Present at Medical Device Investor Forum

SAN DIEGO, Nov. 14, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers, announced today that Punit Dhillon, President and CEO, will be presenting at the 6th Annual Medical Device Investor Forum in Irvine, California.


6th Annual Medical Device Investor Forum
Hyatt Regency Irvine
17900 Jamboree Road
Irvine, California, USA 92614
November 15, 2011
4:50 pm PST

In its 6th year, the two-day Orange County based conference will bring together industry professionals and investors in an effort to build funding opportunities for medical device innovations. The forum is intended to open up discussion amongst professionals ranging from established business leaders and key investors to early stage startup medical device venture capitalists.

OncoSec will also be attending the American Israeli Medical Association (AIMA) BioMedTech Conference in Los Angeles, CA.

AIMA – BioMedTech Conference
Skirball Cultural Center
2701 Sepulveda Blvd.
Los Angeles, CA 90049
November 15, 2011

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec's clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at Additional information may also be found at OncoSec's Facebook, Twitter, and LinkedIn sites.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Device Master File for OncoSec Medical System Completed and Submitted to FDA
2. OncoSec Releases Devices for Use in Clinical Trials
3. Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
4. OncoSec Announces Positive Results from Head & Neck and Breast Cancer Trials
5. OncoSec Medical to Attend 6th Annual Fire, Ice and Beyond: The Future of Ablation Therapies Conference
6. OncoSec Medical to Present at Industry and Investor Conferences
7. OncoSec Medical Appoints Engineering Leader
8. OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors
9. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
10. OncoSec Medical Closes $1.1M Financing
11. OncoSec Medical to Present at ROTH 23rd Annual Growth Stock Conference
Post Your Comments:
(Date:11/26/2015)... -- Research and Markets ( ) has announced the ... to 2019 - Rise in Cardiac Disorders and Growing Awareness ... their offering. Boston scientific ... scientific and others. --> The market is ... Boston scientific and others. ...
(Date:11/26/2015)... ) has ... Future Horizons and Growth Strategies in the ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> ) has announced the ... and Growth Strategies in the German Drugs ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... of the "Self Administration of High Viscosity ... ) has announced the addition of ... report to their offering. --> ... the addition of the "Self Administration of ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... 26, 2015 , ... Indosoft Inc., developer and distributor of the world-class Asterisk ... system efficiency and reliability. , The new Q-Suite 6 platform is based on the ... locking itself into a specific piece of software for many key components of the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, one of the ... stellar workplace culture with the company’s Cincinnati office being named a finalist among ... was named a finalist in Cincinnati Business Courier’s 13th annual Greater Cincinnati Best ...
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to ... between the two groups began in 2014 with Vitalalert pledging a portion of every ... founded in 1954 and is an international Christian-based health organization whose mission is to ...
(Date:11/25/2015)... ... November 25, 2015 , ... Wimbledon Health Partners, ... new Wimbledon Athletics Facebook page to educate the public, parents and ... abnormalities. About 2,000 people under the age of 25 die from sudden cardiac ...
(Date:11/25/2015)... ... ... Beddit® has launched a new Android app for use with ... more intuitive SleepScore™ that rates sleep quality on a 100-point scale and makes it ... a proprietary algorithm. Beddit analyzes the data to provide an easy to understand scientific ...
Breaking Medicine News(10 mins):